To the content
3 . 2021

Modern possibilities of Cushing's disease medication control

Abstract

Cushing's disease (CD) is a rare disease with a clinical picture of hypercortisolism, caused by the presence of pituitary tumor or hyperplasia and characterized by hypersecretion of adrenocorticotropic hormone and an increase in cortisol production by the adrenal gland. Surgical treatment is the first line of therapy. But one-third of patients does not achieve remission after surgery. Among the second-line treatment methods a drug therapy is getting larger value. Although modern drug therapy does not always achieve an optimal efficacy and safety profile. Over the last years, the range of medication treatment for CD has expanded significantly. Innovative drugs, either already introduced into practice or at the stage of clinical trials, are getting more and more important in the treatment of CD. The possibility of using drugs of different groups opens up prospects for the development of combination therapy.

Keywords:Cushing's disease, adrenocorticotropic hormone, ACTH hypersecretion, cortisol, hypercortisolism, pituitary adenoma

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

For citation: Andreeva A.V., Antsiferov M.B. Modern possibilities of Cushing's disease medication control. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2021; 10 (3): 66-74. DOI: https://doi.org/10.33029/2304-9529-2021-10-3-66-74 (in Russian)

REFERENCES

1. Itsenko N.M. Tumor hypophisis with polyglandular symptom complex, in connection with the review of the issue of central innervation of autonomic functions. Yugo-Vostochniy vestnik zdravookhraneniya [SouthEastern Bulletin of Healthcare]. 1924; (3-4): 136. (in Russian)

2. Vasyukova E.A., Soskin L.S. Current concepts concerning the pathogenesis and treatment of Itsenko-Cushing disease. Klinicheskaya meditsina [Clinical Medicine]. 1972; 50 (8): 16-21. PMID: 4349774. (in Russian)

3. Nieman L.K. Cushing’s syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol. 2015; 173 (4): M33-8. DOI: https://doi.org/10.1530/EJE-15-0464 PMID: 26156970; PMCID: PMC 4553096.

4. Marova E.I., Arapova S.D., Belaya Zh.E., et al. Itsenko-Cushing’s disease: clinical picture, diagnosis, treatment. Moscow: GEOTAR-Media, 2012: 64 p. (in Russian)

5. Melnichenko G.A., Dedov I.I., Belaia Zh.E., Rozhinskaia L. Ia., Vagapova G.R., Volkova N.I., et al. Cushing’s disease: the clinical features, diagnostics, differential diagnostics, and methods of treatment. Problemy endokrinologii [Problems of Endocrinology]. 2015; 61 (2): 55-77. (in Russian)

6. Espinosa-de-Los-Monteros A.L., Sosa-Eroza E., Espinosa E., Mendoza V., Arreola R., Mercado M. Long-term outcome of the different treatment alternatives for recurrent and persistent Cushing disease. Endocr Pract. 2017; 23 (7): 759-67. DOI: https://doi.org/10.4158/EP171756.OR PMID: 28332874.

7. Ciato D., Mumbach A.G., Paez-Pereda M., Stalla G.K. Currently used and investigational drugs for Cushing’s disease. Expert Opin Investig Drugs. 2017; 26 (1): 75-84. DOI: https://doi.org/10.1080/13543784.2017.126 6338 PMID: 27894193.

8. Grigoriev A.Yu., Azizian V.N., Ivashenko O.V., Nadezhdina E.Yu. The repeated transsphenoidal adenomectomy because of relapse and persistent course of Itsenko-Kushing disease. Neyrokhirurgiya [Neurosurgery]. 2014; (2): 49-53. (in Russian)

9. Braun L.T., Rubinstein G., Zopp S., Vogel F., Schmid-Tannwald C., Pazos Escudero M., et al. Recurrence after pituitary surgery in adult Cushing’s disease: a systematic review on diagnosis and treatment. Endicrine. 2020; 70 (2): 218-31.

10. Fleseriu M., Petersenn S. New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy. J Neurooncol. 2013; 114 (1): 1-11. DOI: https://doi.org/10.1007/s11060-013-1151-1 PMID: 23673515; PMCID: PMC 3724972.

11. Geer E.B., Shafiq I., Gordon M.B., Bonert V., Ayala A., Swerdloff R.S., et al. Biochemical control during long-term follow-up of 230 adult patients with Cushing disease: a multicenter retrospective study. Endocr Pract. 2017; 23 (8): 962-70. DOI: https://doi.org/10.4158/EP171787.OR PMID: 28614003.

12. Marova Yu.I., Manchenko O.V., Voronlsov A.V., Goncharov N.P., Kolesnikova G.S. Experience with radiosurgery used in patients with Cushing’s syndrome without detected pituitary adenoma. Problemy endokrinologii [Problems of Endocrinology]. 2008; (3): 21-7. (in Russian)

13. Pivonello R., De Leo M., Cozzolino A., Colao A. The treatment of Cushing’s disease. Endocr Rev. 2015; 36 (4): 385-6. DOI: https://doi.org/10.1210/er.2013-1048 PMID: 26067718; PMCID: PMC 4523083.

14. Feelders R.A., Newell-Price J., Pivonello R., Nieman L.K., Hofland L.J., Lacroix A. Advances in the medical treatment of Cushing’s syndrome. Lancet Diabetes Endocrinol. 2019; 7 (4): 300-12. DOI: https://doi.org/10.1016/S2213-8587(18)30155-4 PMID: 30033041.

15. Belaya Zh.E. Early diagnosis of endogenous hypercortisolism. Canonical wnt signaling pathway and changes in bone metabolism in glucocorticoid osteoporosis: Diss. Moscow, 2013: 293 p. (in Russian)

16. Liu J.K., Fleseriu M., Delashaw J.B. Jr, Ciric I.S., Couldwell W.T. Treatment options for Cushing disease after unsuccessful transsphenoidal surgery. Neurosurg Focus. 2007; 23 (3): E 8. DOI: https://doi.org/10.3171/foc.2007.23.3.10 PMID: 17961031.

17. Castinetti F., Morange I., Jaquet P., Conte-Devolx B., Brue T. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease. Eur J Endocrinol. 2008; 158 (1): 91-9. DOI: https://doi.org/10.1530/EJE-07-0514 PMID: 18166822.

18. Auchus R.J., Wu Y., Liu J., Peng H.M. 2S, 4R-ketoconazole is the relevant enantiomer of ketoconazole for cortisol synthesis inhibition: steroidogenic P450s inhibition involves multiple mechanisms. In: Poster Presented at the 100th Annual Meeting and Expo of the Endocrine Society (ENDO). Chicago, IL, 2018.

19. Daniel E., Newell-Price J.D. Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing’s syndrome. Eur J Endocrinol. 2015; 172 (6): R 263-80. DOI: https://doi.org/10.1530/EJE-14-1014 PMID: 25637072.

20. Nieman L., Boscaro M., Scaroni C., Deutschbein T., Mezosi E., Dries-sens N., et al. PROMPT: a prospective study to assess efficacy and safety of metyrapone in endogenous Cushing’s syndrome - 12-week interim analysis. In: Poster Presented at the 2020 European Congress of Endocrinology. 2020.

21. Broersen L.H.A., Jha M., Biermasz N.R., Pereira A.M., Dekkers O.M. Effectiveness of medical treatment for Cushing’s syndrome: a systematic review and meta-analysis. Pituitary. 2018; 21 (6): 631-41. DOI: https://doi.org/10.1007/s11102-018-0897-z PMID: 29855779; PMCID: PMC 6244780.

22. Creemers S.G., Feelders R.A., de Jong F.H., Franssen G.J.H., de Rijke Y.B., van Koetsveld P.M., et al. Osilodrostat is a potential novel steroidogenesis inhibitor for the treatment of Cushing syndrome: an in vitro study. J Clin Endocrinol Metab. 2019; 104 (8): 3437-49. DOI: https://doi.org/10.1210/jc.2019-00217 PMID: 31127821.

23. Fleseriu M., Pivonello R., Elenkova A., Salvatori R., Auchus R.J., Feelders R.A., et al. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing’s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes Endocrinol. 2019; 7 (11): 855-65. DOI: https://doi.org/10.1016/S2213-8587(19)30313-4 PMID: 31542384.

24. Pivonello R., Fleseriu M., Newell-Price J., Bertagna X., Findling J., Shimatsu A., et al.; LINC 3 investigators. Efficacy and safety of osilodrostat in patients with Cushing’s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol. 2020; 8 (9): 748 - 61. DOI: https://doi.org/10.1016/S2213-8587(20)30240-0 PMID: 32730798.

25. Heyn J., Geiger C., Hinske C.L., Briegel J., Weis F. Medical suppression of hypercortisolemia in Cushing’s syndrome with particular consideration of etomidate. Pituitary. 2012; 15 (2): 117-25. DOI: https://doi.org/10.1007/s11102-011-0314-3 PMID: 21556813.

26. Eckstein N., Haas B., Hass M.D., Pfeifer V. Systemic therapy of Cushing’s syndrome. Orphanet J Rare Dis. 2014; 9: 122. DOI: https://doi.org/10.1186/s13023-014-0122-8 PMID: 25091295; PMCID: PMC 4237936.

27. Fleseriu M., Biller B.M., Findling J.W., Molitch M.E., Schteingart D.E., Gross C.; SEISMIC Study Investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab. 2012; 97 (6): 2039-49. DOI: https://doi.org/10.1210/jc.2011-3350 PMID: 22466348.

28. Tritos N.A., Biller B.M. Advances in medical therapies for Cushing’s syndrome. Discov Med. 2012; 13 (69): 171-9. PMID: 22369976.

29. Patel Y.C. Somatostatin and its receptor family. Front Neuro-endocrinol. 1999; 20 (3): 157-98. DOI: https://doi.org/10.1006/frne.1999.0183 PMID: 10433861.

30. Batista D.L., Zhang X., Gejman R., Ansell P.J., Zhou Y., Johnson S.A., et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab. 2006; 91 (11): 4482-8. DOI: https://doi.org/10.1210/jc.2006-1245 PMID: 16940446.

31. Hofland L.J., van der Hoek J., Feelders R., van Aken M.O., van Koetsveld P.M., Waaijers M., et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol. 2005; 152 (4): 645-54. DOI: https://doi.org/10.1530/eje.L01876 PMID: 15817922.

32. van der Hoek J., Waaijers M., van Koetsveld P.M., Sprij-Mooij D., Feelders R.A., Schmid H.A., et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab. 2005; 289 (2): E 278-87. DOI: https://doi.org/10.1152/ajpendo.00004.2005 PMID: 15769796.

33. de Bruin C., Feelders R.A., Lamberts S.W., Hofland L.J. Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s syndrome. Rev Endocr Metab Disord. 2009; 10 (2): 91-102. DOI: https://doi.org/10.1007/s11154-008-9082-4 PMID: 18642088.

34. Vasyukova E.A., Zefirova G.S., Ibragimova G.V., Mkrtumyan A.M., Khalkina M.B. Bromocryptin in the treatment of itsenko-cushing’s disease. Klinicheskaya meditsina [Clinical Medicine]. 1979; (6): 65-9. PMID: 224516. (in Russian)

35. Colao A., Petersenn S., Newell-Price J., Findling J.W., Gu F, Maldonado M., Schoenherr U., et al.; Pasireotide B 2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012; 366 (10): 914-24. DOI: https://doi.org/10.1056/NEJMoa1105743 PMID: 22397653.

36. Reznik Y., Bertherat J., Borson-Chazot F., Brue T., Chanson P., Cortet-Rudelli C., et al. Management of hyperglycaemia in Cushing’s disease: experts’ proposals on the use of pasireotide. Diabetes Metab. 2013; 39 (1): 34-41. DOI: https://doi.org/10.1016/j.diabet.2012.10.005 PMID: 23228667.

37. Lacroix A., Gu F., Gallardo W., Pivonello R., Yu Y., Witek P., et al.; Pasireotide G2304 Study Group. Efficacy and safety of once-monthly pasireotide in Cushing’s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol. 2018; 6 (1): 17-26. DOI: https://doi.org/10.1016/S2213-8587(17)30326-1 PMID: 29032078.

38. Plockinger U., Hoffmann U., Geese M., Lupp A., Buchfelder M., Flitsch J., et al. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. Eur J Endocrinol. 2012; 166 (2): 223-34. DOI: https://doi.org/10.1530/EJE-11-0737 PMID: 22065857.

39. Pivonello R., Ferone D., de Herder W.W., Kros J.M., De Caro M.L., Arvigo M., et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab. 2004; 89 (5): 2452-62. DOI: https://doi.org/10.1210/jc.2003-030837 PMID: 15126577.

40. Lila A.R., Gopal R.A., Acharya S.V., George J., Sarathi V., Bandgar T., et al. Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocr Pract. 2010; 16 (6): 968-76. DOI: https://doi.org/10.4158/EP10031. OR PMID: 20497937.

41. Ferriere A., Cortet C., Chanson P., Delemer B., Caron P., Chabre O., et al. Cabergoline for Cushing’s disease: a large retrospective multicenter study. Eur J Endocrinol. 2017; 176: 305-14. DOI: https://doi.org/10.1530/EJE-16-0662

42. Sek K.S., Deepak D.S., Lee K.O. Use of cabergoline for the management of persistent Cushing’s disease in pregnancy. BMJ Case Rep. 2017. DOI: https://doi.org/10.1136/bcr-2016-217855

43. Khalil H.S., Mitev V., Vlaykova T., Cavicchi L., Zhelev N. Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance. J Biotechnol. 2015; 202: 40-9. DOI: https://doi.org/10.1016/j.jbiotec.2015.02.032 PMID: 25747275.

44. Liu N.A., Jiang H., Ben-Shlomo A., Wawrowsky K., Fan X.M., Lin S., et al. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci USA. 2011; 108 (20): 8414-9. DOI: https://doi.org/10.1073/pnas.1018091108 PMID: 21536883; PMCID: PMC 3100964.

45. Paez-Pereda M., Kovalovsky D., Hopfner U., Theodoropoulou M., Pagotto U., Uhl E., et al. Retinoic acid prevents experimental Cushing syndrome. J Clin Invest. 2001; 108 (8): 1123-31. DOI: https://doi.org/10.1172/JCI11098 PMID: 11602619; PMCID: PMC 209498.

46. Pecori Giraldi F., Ambrogio A.G., Andrioli M., Sanguin F., Kara-mouzis I., Corsello S.M., et al. Potential role for retinoic acid in patients with Cushing’s disease. J Clin Endocrinol Metab. 2012; 97 (10): 3577-83. DOI: https://doi.org/10.1210/jc.2012-2328

47. Karamouzis I., Pontercorvi A. Erratum in. J Clin Endocrinol Metab. 2013; 98 (3): 1294. PMID: 22851491.

48. Feelders R.A., de Bruin C., Pereira A.M., Romijn J.A., Netea-Maier R.T., Hermus A.R., et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing’s disease. N Engl J Med. 2010; 362 (19): 1846-8. DOI: https://doi.org/10.1056/NEJMc1000094 PMID: 20463350.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Ametov Alexander S.
Honored Scientist of the Russian Federation, Doctor of Medical Sciences, Professor, Head of Subdepartment of Endocrinology, Head of the UNESCO Network Chair on the subject «Bioethics of diabetes as a global problem» of the Russian Medical Academy of Continuous Professional Education (Moscow)
Вскрытие

Journals of «GEOTAR-Media»